Kornitzer Capital Management’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$46.2M Buy
331,796
+2,942
+0.9% +$412K 0.99% 25
2025
Q4
$40.4M Sell
328,854
-5,622
-2% -$683K 0.84% 28
2025
Q3
$37.1M Sell
334,476
-15,010
-4% -$1.71M 0.75% 30
2025
Q2
$38.7M Sell
349,486
-5,028
-1% -$535K 0.78% 29
2025
Q1
$39.7M Sell
354,514
-5,189
-1% -$535K 0.82% 29
2024
Q4
$33.2M Sell
359,703
-11,150
-3% -$1M 0.65% 34
2024
Q3
$31.1M Sell
370,853
-25
-0% -$1.91K 0.57% 39
2024
Q2
$25.4M Sell
370,878
-4,005
-1% -$267K 0.48% 46
2024
Q1
$27.5M Sell
374,883
-442
-0.1% -$34K 0.5% 44
2023
Q4
$30.4M Sell
375,325
-1,170
-0.3% -$91K 0.59% 36
2023
Q3
$28.2M Sell
376,495
-743
-0.2% -$57.1K 0.58% 34
2023
Q2
$29.1M Sell
377,238
-500
-0.1% -$39.9K 0.57% 35
2023
Q1
$31.3M Sell
377,738
-1,413
-0.4% -$117K 0.63% 32
2022
Q4
$32.6M Sell
379,151
-2,305
-0.6% -$183K 0.66% 29
2022
Q3
$23.5M Buy
381,456
+1,893
+0.5% +$119K 0.5% 44
2022
Q2
$23.5M Buy
379,563
+30,915
+9% +$1.91M 0.47% 50
2022
Q1
$20.7M Buy
348,648
+3,126
+0.9% +$200K 0.34% 94
2021
Q4
$25.1M Sell
345,522
-3,390
-1% -$233K 0.37% 82
2021
Q3
$24.4M Buy
348,912
+1,192
+0.3% +$83.7K 0.37% 79
2021
Q2
$23.9M Buy
347,720
+15,410
+5% +$1.03M 0.36% 89
2021
Q1
$21.5M Buy
332,310
+35,645
+12% +$2.3M 0.34% 103
2020
Q4
$17.3M Buy
296,665
+31,592
+12% +$1.91M 0.29% 123
2020
Q3
$16.8M Buy
265,073
+27,675
+12% +$1.92M 0.33% 102
2020
Q2
$18.3M Buy
237,398
+40,213
+20% +$3.08M 0.37% 91
2020
Q1
$14.7M Buy
197,185
+4,270
+2% +$295K 0.35% 102
2019
Q4
$12.5M Buy
192,915
+965
+0.5% +$62.8K 0.22% 142
2019
Q3
$12.2M Buy
191,950
+5,780
+3% +$378K 0.22% 142
2019
Q2
$12.6M Sell
186,170
-2,420
-1% -$159K 0.22% 142
2019
Q1
$12.3M Buy
188,590
+14,165
+8% +$941K 0.22% 141
2018
Q4
$10.9M Buy
174,425
+265
+0.2% +$18.5K 0.22% 141
2018
Q3
$13.4M Buy
174,160
+160
+0.1% +$12.1K 0.21% 146
2018
Q2
$12.3M Buy
174,000
+710
+0.4% +$50.1K 0.21% 142
2018
Q1
$13.1M Sell
173,290
-1,355
-0.8% -$108K 0.22% 139
2017
Q4
$12.5M Sell
174,645
-56,979
-25% -$4.33M 0.21% 144
2017
Q3
$18.8M Sell
231,624
-11,152
-5% -$853K 0.33% 102
2017
Q2
$17.2M Buy
242,776
+42,555
+21% +$2.83M 0.3% 109
2017
Q1
$13.6M Buy
200,221
+146,706
+274% +$10.3M 0.24% 127
2016
Q4
$3.83M Sell
53,515
-7,140
-12% -$531K 0.07% 258
2016
Q3
$4.8M Buy
60,655
+4,485
+8% +$364K 0.09% 254
2016
Q2
$4.69M Buy
56,170
+18,065
+47% +$1.6M 0.08% 250
2016
Q1
$3.5M Buy
38,105
+16,675
+78% +$1.5M 0.06% 267
2015
Q4
$2.17M Buy
21,430
+150
+0.7% +$15.6K 0.04% 303
2015
Q3
$2.09M Sell
21,280
-15
-0.1% -$1.67K 0.03% 318
2015
Q2
$2.49M Sell
21,295
-1,125
-5% -$123K 0.03% 315
2015
Q1
$2.2M Sell
22,420
-5,650
-20% -$574K 0.03% 315
2014
Q4
$2.65M Sell
28,070
-111,225
-80% -$11.5M 0.03% 300
2014
Q3
$14.8M Sell
139,295
-42,817
-24% -$4.19M 0.17% 150
2014
Q2
$15.1M Buy
182,112
+14,650
+9% +$1.14M 0.16% 157
2014
Q1
$11.9M Sell
167,462
-31,475
-16% -$2.47M 0.13% 187
2013
Q4
$14.9M Sell
198,937
-25,350
-11% -$1.77M 0.16% 152
2013
Q3
$14.1M Sell
224,287
-613
-0.3% -$36.6K 0.16% 148
2013
Q2
$11.5M Buy
+224,900
New +$11.7M 0.15% 161

Other funds holding GILD

Kornitzer Capital Management's GILD Position: Q1 2026 in Review

Kornitzer Capital Management increased its Gilead Sciences (GILD) stake by 0.89% in Q1 2026, buying an estimated $412K and bringing the position to 331,796 shares worth $46.2M. The position accounts for 0.99% of the portfolio, ranked #25.

Kornitzer Capital Management first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Kornitzer Capital Management held 331,796 shares of Gilead Sciences worth $46.2M as of Q1 2026.
  • Kornitzer Capital Management bought 2,942 Gilead Sciences shares in Q1 2026, an estimated $412K.
  • Gilead Sciences made up 0.99% of Kornitzer Capital Management's portfolio in Q1 2026, its #25 holding.
  • Kornitzer Capital Management first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
  • 2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Kornitzer Capital Management's 13F filing for Q1 2026, filed 30 Apr 2026.